Computational Identification of Active Drug Metabolites for Human Protein Targets

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: Not formally reported; descriptive proportions only. High proportion of active metabolites demonstrated potencies below 100 nM

• Primary Outcome: 26% of all drug-metabolite-target combinations contain metabolites with retained or increased bioactivity relative to their parent drugs

• Nnt Or Sensitivity: Not applicable to this study design; no NNT, sensitivity, or hazard ratio reported. Key descriptive metrics: 26% prevalence of active metabolites; enrichment of O-demethylation and N-demethylation (tertiary nitrogen) transformations; enrichment in membrane receptor target class

• Confidence Interval: Not reported

Clinical Application

The computational framework and open dataset are immediately usable by drug discovery teams. Clinical translation requires prospective in vivo validation studies to confirm that identified active metabolites achieve pharmacologically relevant systemic exposures. Integration into routine DMPK workflows is feasible given the open data availability In the Australian context, the TGA requires characterisation of major metabolites (>10% of drug-related material) as part of regulatory submissions, consistent with ICH M3(R2) and ICH S9 guidelines. The findings of this study are directly relevant to TGA regulatory dossier preparation, particularly for drugs undergoing O- or N-demethylation. For PBS listing, active metabolites contributing to efficacy may influence pharmacoeconomic modelling. RACGP prescribers should be aware that for drugs in the membrane receptor class (e.g., GPCRs, ion channels) — common in cardiovascular and CNS pharmacotherapy — active metabolites may contribute meaningfully to clinical effect, with implications for dose adjustment in CYP-polymorphic patients or those on CYP-inhibiting co-medications. This is particularly relevant for drugs metabolised by CYP2D6 or CYP3A4, which are common in Australian clinical practice. Primarily applicable to medicinal chemists, DMPK scientists, and pharmacologists involved in drug discovery and development. Indirectly relevant to clinical pharmacologists and pharmacovigilance specialists assessing the contribution of metabolites to drug efficacy and safety in patients

Abstract

Understanding drug metabolism helps mitigate toxicity risks and anticipate pharmacological effects beyond the parent compound. Here, we explore high-confidence in vitro human bioactivity annotations from the public domain associated with a curated data set of drug-metabolite pairs. Our findings show that 26% of all drug-metabolite-target combinations contain metabolites with retained or increased bioactivity relative to their parent drugs, showing a high proportion of active metabolites with potencies below 100 nM. Moreover, these active metabolites display similar predicted physicochemical and ADME properties to their parent drugs, indicating that their biological activity may be preserved in vivo. Two key features of the identified active metabolites are noted: (1) the metabolite is more likely to be formed via an O-demethylation or an N-demethylation at a tertiary nitrogen, and (2) these drug-metabolite pairs are frequently active against the membrane receptor target class. To support further research in this area, we make our data compilation, including pairs with identified active metabolites and recorded bioactivity data, openly available.

References

1. 1.Larsson, S., Mercado, R., Winiwarter, S., & Miljković, F. (2026). Computational identification of active drug metabolites for human protein targets. Molecular Pharmaceutics. Advance online publication. https://doi.org/10.1021/acs.molpharmaceut.6c00258